NO20075044L - Nytt salt av kinuclidinderivat - Google Patents
Nytt salt av kinuclidinderivatInfo
- Publication number
- NO20075044L NO20075044L NO20075044A NO20075044A NO20075044L NO 20075044 L NO20075044 L NO 20075044L NO 20075044 A NO20075044 A NO 20075044A NO 20075044 A NO20075044 A NO 20075044A NO 20075044 L NO20075044 L NO 20075044L
- Authority
- NO
- Norway
- Prior art keywords
- acid
- pharmaceutical
- tartaric
- active ingredient
- fresh salt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 2
- CKESBQSMUJEOSP-UHFFFAOYSA-N 2,3-dihydroxy-2-(4-methylbenzoyl)butanedioic acid Chemical compound CC1=CC=C(C(=O)C(O)(C(O)C(O)=O)C(O)=O)C=C1 CKESBQSMUJEOSP-UHFFFAOYSA-N 0.000 abstract 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 abstract 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 abstract 1
- FBOUYBDGKBSUES-FCHUYYIVSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (1r)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-FCHUYYIVSA-N 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 abstract 1
- 229940092714 benzenesulfonic acid Drugs 0.000 abstract 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 abstract 1
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 abstract 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Et syreaddisjonssalt dannet fra (-)-(1R)-1-fenyl-1,2,3,4-tetrahydroisokinolin-2-karboksylsyre-(3R)-kinuklidin-3-yl-ester og en syre valgt fra gruppen bestående av (-)-(2S,3S)-vinsyre, (+)(2S,3S)-di-o-benzoyl-vinsyre, (+)-(2S,3S)-di-o(4-metylbenzoyl)vinsyre, (-)-L-fenylalanin, benzensulfonsyre, sykloheksansulfamsyre, hydrobromsyre, naftalen-2-sulfonsyre, sebacinsyre, (+)-kamfer-10-sulfonsyre, p-toluensulfonsyre, etansulfonsyre, metansulfonsyre og metylfosfat. Dette salt viser ikke noe hygroskopisitet i et slikt nivå som ikke er ønskelig for anvendelse som et farmasøytisk middel eller en aktiv bestanddel av et farmasøytisk middel, og er derfor en uhyre anvendbar forbindelse for anvendelse som et farmasøytisk middel eller en aktiv bestanddel av et farmasøytisk middel.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005063405 | 2005-03-08 | ||
| JP2005088872A JP3701964B1 (ja) | 2005-03-08 | 2005-03-25 | キヌクリジン誘導体の新規な塩 |
| PCT/JP2006/304241 WO2006095671A1 (ja) | 2005-03-08 | 2006-03-06 | キヌクリジン誘導体の新規な塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075044L true NO20075044L (no) | 2007-12-05 |
Family
ID=34940702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075044A NO20075044L (no) | 2005-03-08 | 2007-10-05 | Nytt salt av kinuclidinderivat |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7176219B2 (no) |
| EP (1) | EP1700858B1 (no) |
| JP (2) | JP3701964B1 (no) |
| KR (1) | KR20070110128A (no) |
| AR (1) | AR055741A1 (no) |
| AT (1) | ATE396992T1 (no) |
| AU (1) | AU2006221451A1 (no) |
| BR (1) | BRPI0608843A2 (no) |
| CA (1) | CA2599872A1 (no) |
| DE (1) | DE602005007176D1 (no) |
| ES (1) | ES2306030T3 (no) |
| IL (1) | IL185470A0 (no) |
| NO (1) | NO20075044L (no) |
| PL (1) | PL1700858T3 (no) |
| PT (1) | PT1700858E (no) |
| RU (1) | RU2007137064A (no) |
| TW (1) | TW200714599A (no) |
| WO (1) | WO2006095671A1 (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137358A1 (en) * | 1996-11-05 | 2010-06-03 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
| CA2599158C (en) * | 2005-02-25 | 2011-01-25 | Astellas Pharma Inc. | Pharmaceutical agent comprising solifenacin |
| JP3701964B1 (ja) | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| CZ300692B6 (cs) * | 2006-12-22 | 2009-07-15 | Zentiva, A. S. | Zpusob prípravy solifenacinu |
| KR101653548B1 (ko) * | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| PL3067353T3 (pl) | 2008-07-29 | 2018-04-30 | Krka, D.D., Novo Mesto | Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2014022139A1 (en) * | 2012-07-31 | 2014-02-06 | University Of Massachusetts Medical School | Methods for identifying agents for treating smooth muscle disorders and compositions thereof |
| JP2022504228A (ja) | 2018-10-03 | 2022-01-13 | テサロ， インコーポレイテッド | ニラパリブ遊離塩基の結晶形態 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| GB9600063D0 (en) | 1996-01-03 | 1996-03-06 | Fujisawa Pharmaceutical Co | Guaridine derivatives |
| JPH107675A (ja) | 1996-06-21 | 1998-01-13 | Yamanouchi Pharmaceut Co Ltd | 新規なイソキノリン誘導体又はその塩 |
| JP2002104968A (ja) | 2000-09-28 | 2002-04-10 | Senju Pharmaceut Co Ltd | 毛様体筋の緊張緩和剤 |
| PT1405638E (pt) * | 2001-07-10 | 2011-04-06 | Astellas Pharma Inc | Composição farmacêutica compreendendo 1-fenil-1,2,3,4 tetrahidroisoquinolino- 2-carboxilato de quinuclidin-3'-ilo para tratamento de cistite intersticial e/ou prostatite não bacteriana |
| JP3701964B1 (ja) | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
-
2005
- 2005-03-25 JP JP2005088872A patent/JP3701964B1/ja not_active Expired - Lifetime
- 2005-04-04 ES ES05252102T patent/ES2306030T3/es not_active Expired - Lifetime
- 2005-04-04 EP EP05252102A patent/EP1700858B1/en not_active Expired - Lifetime
- 2005-04-04 DE DE602005007176T patent/DE602005007176D1/de not_active Expired - Fee Related
- 2005-04-04 AT AT05252102T patent/ATE396992T1/de not_active IP Right Cessation
- 2005-04-04 PL PL05252102T patent/PL1700858T3/pl unknown
- 2005-04-04 PT PT05252102T patent/PT1700858E/pt unknown
- 2005-05-13 US US11/128,238 patent/US7176219B2/en not_active Expired - Fee Related
-
2006
- 2006-02-22 TW TW095105953A patent/TW200714599A/zh unknown
- 2006-03-03 AR ARP060100801A patent/AR055741A1/es unknown
- 2006-03-06 RU RU2007137064/04A patent/RU2007137064A/ru not_active Application Discontinuation
- 2006-03-06 KR KR1020077022738A patent/KR20070110128A/ko not_active Withdrawn
- 2006-03-06 WO PCT/JP2006/304241 patent/WO2006095671A1/ja not_active Ceased
- 2006-03-06 CA CA002599872A patent/CA2599872A1/en not_active Abandoned
- 2006-03-06 JP JP2007507092A patent/JP4605218B2/ja not_active Expired - Fee Related
- 2006-03-06 AU AU2006221451A patent/AU2006221451A1/en not_active Abandoned
- 2006-03-06 BR BRPI0608843-0A patent/BRPI0608843A2/pt not_active Application Discontinuation
-
2007
- 2007-08-23 IL IL185470A patent/IL185470A0/en unknown
- 2007-10-05 NO NO20075044A patent/NO20075044L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006095671A1 (ja) | 2006-09-14 |
| US7176219B2 (en) | 2007-02-13 |
| US20060205770A1 (en) | 2006-09-14 |
| EP1700858B1 (en) | 2008-05-28 |
| CA2599872A1 (en) | 2006-09-14 |
| ATE396992T1 (de) | 2008-06-15 |
| DE602005007176D1 (de) | 2008-07-10 |
| JP4605218B2 (ja) | 2011-01-05 |
| JPWO2006095671A1 (ja) | 2008-08-14 |
| RU2007137064A (ru) | 2009-04-20 |
| JP2008308406A (ja) | 2008-12-25 |
| AR055741A1 (es) | 2007-09-05 |
| JP3701964B1 (ja) | 2005-10-05 |
| TW200714599A (en) | 2007-04-16 |
| AU2006221451A1 (en) | 2006-09-14 |
| KR20070110128A (ko) | 2007-11-15 |
| IL185470A0 (en) | 2008-01-06 |
| PT1700858E (pt) | 2008-07-17 |
| ES2306030T3 (es) | 2008-11-01 |
| BRPI0608843A2 (pt) | 2010-02-02 |
| EP1700858A1 (en) | 2006-09-13 |
| PL1700858T3 (pl) | 2008-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075044L (no) | Nytt salt av kinuclidinderivat | |
| SG10202102306TA (en) | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| EA202092383A1 (ru) | Ингибиторы комплемента на основе замещенного бензофурана, бензопиррола, бензотиофена и их структурных производных | |
| EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| NO20062691L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
| NO20090581L (no) | Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
| MX2009008540A (es) | Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina. | |
| NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
| WO2008005368A3 (en) | Piperazines as p2x7 antagonists | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
| NO20090580L (no) | Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
| NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| NO20083250L (no) | Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner | |
| EA201390717A1 (ru) | 3-(аминоарил)пиридиновые соединения | |
| WO2010030704A3 (en) | Antibacterial aminoglycoside analogs | |
| NO20090289L (no) | Inhibitorer av akt (proteinkinase B) | |
| MX2009010302A (es) | Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion. | |
| NO20091817L (no) | Kinase inhibitorer | |
| TW200643020A (en) | Crystalline form of a quinolinone-carboxamide compound | |
| EA201300617A1 (ru) | β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ | |
| EA201201662A1 (ru) | Дизамещенные тетрагидрофуранильные соединения в качестве антагонистов брадикининового рецептора в1 | |
| NO20055631L (no) | Doseringsform inneholdende pantoprazol som aktiv ingrediens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |